Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2015 Feb 5;35(4):855–864. doi: 10.1161/ATVBAHA.114.304627

Fig. 3. Anti-angiogenic activity of VLN-NP in the retina.

Fig. 3

A: Expression of VLN in the mouse retinas was measured using Western blot analysis at 1, 2, 3 and 4 weeks following an intravitreal injection of VLN-NP. B: Representative retinal angiographs of Vldlr−/− (VKO) mice(upper panels, ×40; lower panels, higher magnification of the boxed areas). VLN-NP was injected into the VKO eyes on P10, with LN-NP as control. Retinal angiography was performed on P30. C: Quantification of intra-retinal neovascular blebs (IRN blebs) in VKO mice treated with VLN-NP or LN-NP. **p<0.01, n=6. D: Immunostaining of BS-1 lectin (green) in VKO retinal sections. The nuclei were counterstained with DAPI (blue) (×200). Arrows indicate abnormal vessels in the retinas. GCL: ganglion cell layer; INL: inner nuclear layer; ONL: outer nuclear layer; RPE: retinal pigment epithelium. E–H: VLN-NP or LN-NP was intravitreally injected into OIR mice on P12 and retinal NV analyzed at P17. E: Representative retinal angiographs (upper panels, ×40; lower panels, higher magnification of the boxed areas). F: Quantification of non-perfusion area in the retina. **p<0.01, n=6. G: Representative retinal sections with H&E staining. Arrows indicate pre-retinal vascular cells (×200). H: Quantification of pre-retinal vascular cells. **p<0.01, n=6.